Ovarian tumor initiating cell populations persist following paclitaxel and carboplatin chemotherapy treatment in vivo
| Autor: | Bo R. Rueda, Kashmira Kulkarni-Datar, Rosemary Foster, Sandra Orsulic |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Paclitaxel medicine.medical_treatment Cell Gene Expression Antineoplastic Agents Biology Carboplatin Mice Ovarian tumor chemistry.chemical_compound Antigens CD Cancer stem cell Cell Line Tumor Internal medicine medicine Animals Antigens Ly AC133 Antigen Cell Proliferation Glycoproteins Ovarian Neoplasms Chemotherapy Cell Cycle Membrane Proteins medicine.disease Tumor Burden Disease Models Animal medicine.anatomical_structure chemistry Neoplastic Stem Cells Female Stem cell Peptides Ovarian cancer |
| Zdroj: | Cancer Letters. 339:237-246 |
| ISSN: | 0304-3835 |
| DOI: | 10.1016/j.canlet.2013.06.014 |
| Popis: | Development of recurrent platinum resistant disease following chemotherapy presents a challenge in managing ovarian cancer. Using tumors derived from genetically defined mouse ovarian cancer cells, we investigated the stem cell properties of residual cells post-chemotherapy. Utilizing CD133 and Sca-1 as markers of candidate tumor initiating cells (TIC), we determined that the relative levels of CD133+ and Sca-1+ cells were unaltered following chemotherapy. CD133+ and Sca-1+ cells exhibited increased stem cell-related gene expression, were enriched in G0/G1-early S phase and exhibited increased tumor initiating capacity, giving rise to heterogeneous tumors. Our findings suggest that residual TICs may contribute to recurrent disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect